TRT Telehealth in 2026: How to Compare Marek Health, Hone, Maximus and Defy Without the Marketing Spin
What is TRT?
Testosterone Replacement Therapy (TRT) is the clinical replacement of testosterone in men whose endogenous production is insufficient — a condition diagnosed as hypogonadism. In the UK, diagnosis requires two morning testosterone measurements below 12 nmol/L with symptoms, per NICE guideline NG242. [6]
The term “TRT” is also used colloquially to describe testosterone optimisation in men with low-normal levels (12–16 nmol/L) who report symptomatic fatigue, poor libido, reduced muscle mass, and mood deterioration. This broader optimisation framing — pioneered in the US by direct-to-consumer telehealth platforms — is where the regulatory and clinical tension sits.
Testosterone is a controlled drug (Schedule 4) in the UK, requiring a prescription from a licensed clinician.
Key Takeaways
- TRT in the UK requires a prescription from a licensed GP or endocrinologist. Testosterone is a Schedule 4 controlled drug.
- The TRAVERSE trial (2023, n=5,246) is the first large cardiovascular safety RCT for TRT in men with hypogonadism, showing non-inferiority to placebo for MACE. [3]
- US telehealth platforms (Marek Health, Hone, Maximus, Defy Medical) are not authorised to prescribe to UK patients — they operate under US FDA/DEA frameworks, which do not extend to the UK.
- UK alternatives include private GP clinics (Optimale, Leger, Balance My Hormones), some of which now offer telehealth-initiated TRT with MHRA-compliant monitoring.
- Enclomiphene (a SERM that stimulates endogenous testosterone production without suppressing fertility) is an emerging alternative for younger men — available off-label in the UK.
- Monitoring requirements: FBC (haematocrit), PSA, testosterone levels, and symptom review at minimum 3-monthly initially.
How TRT Works: Mechanism of Action
The hypothalamic-pituitary-gonadal (HPG) axis regulates testosterone production. The hypothalamus releases GnRH, which stimulates the pituitary to release LH and FSH. LH drives Leydig cells in the testes to produce testosterone; FSH supports spermatogenesis.
Exogenous testosterone (injected, topical, or implanted) replaces the signal but suppresses the HPG axis via negative feedback — LH and FSH fall, reducing endogenous production and spermatogenesis. This is the core trade-off in conventional TRT: effective hormone replacement with fertility implications.
Enclomiphene works upstream: as a selective oestrogen receptor modulator (SERM), it blocks oestrogen’s negative feedback on the pituitary, increasing LH and FSH output and therefore driving endogenous testosterone production. Fertility is preserved because spermatogenesis is not suppressed. [4] This makes it an important option for men who want testosterone optimisation without permanently suppressing fertility.
Evidence: What the Research Shows
The Testosterone Trials (TTrials)
The Testosterone Trials (7 coordinated RCTs in men ≥65 with low testosterone) showed improvements in sexual function, walking distance, bone density, and mood with testosterone therapy. [2] Anaemia and bone outcomes were particularly strong. Effects on cognitive function were not significant. These remain the largest quality evidence base for TRT in older men.
TRAVERSE Trial — Cardiovascular Safety
The TRAVERSE trial (n=5,246, men 45–80 with hypogonadism and cardiovascular risk) is the definitive cardiovascular safety study. Testosterone showed non-inferiority to placebo for MACE — the concern that TRT increases heart attack or stroke risk was not borne out. [3] TRAVERSE did find increased rates of atrial fibrillation, pulmonary embolism, and acute kidney injury — important safety signals requiring monitoring.
Dosage and Protocol
| Formulation | Typical dose | Frequency | UK availability |
|---|---|---|---|
| Testosterone cypionate / enanthate (injection) | 100–200 mg | Weekly or fortnightly | Private prescription |
| Testosterone undecanoate (Nebido injection) | 1,000 mg | Every 10–14 weeks | NHS + private |
| Testosterone gel (Testogel, Tostran) | 40–80 mg/day | Daily | NHS + private |
| Enclomiphene | 12.5–25 mg | Daily | Off-label, private only |
Monitoring: Testosterone level (mid-cycle for injections), haematocrit (polycythaemia risk), PSA (prostate safety), LFTs at baseline.
Safety, Side Effects, and Drug Interactions
Common: Acne, increased haematocrit (thickened blood — managed with dose adjustment and phlebotomy), testicular atrophy and reduced fertility (with exogenous testosterone), mood fluctuations.
Serious (TRAVERSE signal): Increased risk of atrial fibrillation, pulmonary embolism. Polycythaemia (haematocrit >54%) increases clotting risk — haematocrit monitoring is mandatory.
Contraindications: Active prostate cancer, severe lower urinary tract symptoms, haematocrit >54%, untreated obstructive sleep apnoea (worsened by testosterone).
UK Regulatory Status
Testosterone is a Schedule 4 Part 2 controlled drug under the Misuse of Drugs Regulations 2001, regulated by the MHRA. It requires a prescription from a UK-licensed clinician. NHS prescribing follows NICE NG242 criteria; private prescribing follows MHRA-approved clinical judgment.
The FSA does not regulate testosterone — it is entirely within MHRA jurisdiction. Testosterone is not available as a supplement in the UK. Any product marketed as “testosterone booster” containing testosterone itself is illegal without prescription.
How to Stack TRT with Other Protocols
hCG: Human chorionic gonadotropin (hCG) mimics LH signalling, partially maintaining testicular function during exogenous TRT. Used by some practitioners to preserve intratesticular testosterone and testicular volume. Requires private prescription.
Anastrozole (aromatase inhibitor): Some men convert excess testosterone to oestradiol, causing high-oestrogen symptoms. Anastrozole, used at low dose, suppresses aromatisation. Not universally required — only with confirmed high oestradiol alongside symptoms.
GLP-1s: Weight loss from GLP-1 therapy often raises endogenous testosterone by reducing adipose aromatase activity. Some men find their testosterone improves meaningfully with weight loss alone — worth assessing before adding exogenous testosterone. See our GLP-1 guide.
Rapamycin: No direct interaction. Some clinicians include rapamycin in broader longevity stacks alongside TRT. See our rapamycin PEARL trial article.
Find a UK Practitioner Who Specialises in TRT
UK private TRT services are growing. Proven Longevity’s directory lists practitioners offering full monitoring and MHRA-compliant prescribing.
Frequently Asked Questions
Is TRT safe for my heart? The TRAVERSE trial (2023) showed TRT was non-inferior to placebo for major cardiovascular events in men with hypogonadism. It did show increased risks of atrial fibrillation and pulmonary embolism — these are managed through monitoring and appropriate patient selection.
Can I access US TRT telehealth services (Marek, Hone, Maximus) from the UK? These platforms are licensed under US FDA and DEA frameworks and cannot legally prescribe to UK-based patients. UK patients must use MHRA-registered prescribers.
What is enclomiphene and how does it differ from TRT? Enclomiphene stimulates endogenous testosterone production by blocking oestrogen’s negative feedback on the pituitary. It raises LH and FSH, driving natural production without suppressing spermatogenesis. It is an off-label prescription in the UK — an option for younger men who want testosterone optimisation while preserving fertility.
What monitoring do I need on TRT? At minimum: testosterone level, haematocrit, PSA (if over 40), FBC, and symptom review at 3 months post-initiation, then 6-monthly when stable.
References
- Bhasin S, et al. Testosterone Therapy in Men with Hypogonadism: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2018;103(5):1715–1744. PubMed 29562364
- Snyder PJ, et al. Effects of Testosterone Treatment in Older Men (Testosterone Trials). N Engl J Med. 2016;374(7):611–624. PubMed 26886521
- Lincoff AM, et al. Cardiovascular Safety of Testosterone-Replacement Therapy (TRAVERSE Trial). N Engl J Med. 2023;389(2):107–117. PubMed 37326322
- Coward RM, et al. Enclomiphene citrate stimulates testosterone production. Fertil Steril. 2013;100(1):138–145. PubMed 23566291
- MHRA. Testosterone replacement therapy prescribing information. eMC product 5385
- NHS England. Testosterone deficiency in men: NICE guideline NG242. 2023. NICE NG242
- Khera M, et al. Adult-Onset Hypogonadism. Mayo Clin Proc. 2016;91(7):908–926. PubMed 27387069
- Zitzmann M, et al. Long-term treatment of hypogonadal men with testosterone cypionate. Eur J Endocrinol. 2006;154(2):293–303. PubMed 16452547